AML
News
CAR T-cell therapy bridges to HSCT in AML patient
A case report suggests an investigational chimeric antigen receptor (CAR) T-cell therapy can provide a bridge to transplant in relapsed/refractory...
News
Y chromosome gene protects against AML
Researchers have discovered the first leukemia-protective gene that is specific to the Y chromosome, according to an article published in Nature...
Commentary
Improving survival in older AML patients
Newer therapies and accurate predictive models will be key to treating elderly patients with AML.
News
Potential therapeutic target for type of AML
New research suggests SHARP1 may be a therapeutic target in MLL-AF6 acute myeloid leukemia (AML). Researchers found that SHARP1, a circadian...
News
GO approved to treat AML in Europe
The European Commission has authorized use of gemtuzumab ozogamicin (GO, Mylotarg™) as a treatment for patients with acute myeloid leukemia (AML...
News
Art education benefits blood cancer patients
New research suggests a bedside visual art intervention (BVAI) can reduce pain and anxiety in inpatients with hematologic malignancies, including...
Conference Coverage
BET inhibitor has lasting effects in AML, MM
CHICAGO—A BET inhibitor can have potent and long-lasting effects against leukemia and multiple myeloma (MM), according to researchers. The...
Conference Coverage
Inhibitor outperforms rivals in leukemia, lymphoma
CHICAGO—Preclinical research suggests the pan-FLT3/pan-BTK inhibitor CG’806 is more effective than other kinase inhibitors in fighting certain...
Conference Coverage
Antibody has ‘potent’ effects against AML
CHICAGO—The bispecific antibody APVO436 has demonstrated robust T-cell activation with limited cytokine release in acute myeloid leukemia (AML),...
Conference Coverage
Checkpoint inhibition after HiDAC shows promise in AML
NEWPORT BEACH, CALIF. – Adding pembrolizumab after high-dose cytarabine in relapsed/refractory AML was safe and feasible.
Conference Coverage
5- and 10-day decitabine go head-to-head in poor-risk AML
NEWPORT BEACH, CALIF. – Researchers directly compared 5- and 10-day decitabine in poor-risk older adults with previously untreated AML in a...